DBV Technologies | DBVT - Ativo Circulante





Ativo Circulante Alterar Data
Acadia Pharmaceuticals USD 1.06B 14.31M 2025-12
Alnylam Pharmaceuticals USD 4.05B 97.85M 2025-12
Amarin USD 649.88M 21.55M 2025-12
BioCryst Pharmaceuticals USD 404.35M 48.66M 2025-12
BioMarin Pharmaceutical USD 3.95B 98.95M 2025-12
DBV Technologies USD 88.88M 32.36M 2025-09
Esperion Therapeutics USD 462.57M 102.11M 2025-12
Galectin Therapeutics USD 27.29M 1.83M 2024-06
Halozyme Therapeutics USD 825.21M 503.54M 2025-12
Incyte USD 5.02B 746.01M 2025-12
Insmed USD 1.79B 137.6M 2025-12
Ionis Pharmaceuticals USD 2.99B 471.01M 2025-12
Neurocrine Biosciences USD 2.52B 364.3M 2025-12
PTC Therapeutics USD 2.27B 266.14M 2025-12
Sarepta Therapeutics USD 2.54B 184.37M 2025-12
Ultragenyx Pharmaceutical USD 643.21M 76.58M 2025-09
United Therapeutics USD 3.7B 208.5M 2025-12